2008
DOI: 10.1016/j.ejca.2008.02.028
|View full text |Cite
|
Sign up to set email alerts
|

Management of malignant bowel obstruction

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
212
1
6

Year Published

2012
2012
2018
2018

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 225 publications
(226 citation statements)
references
References 68 publications
4
212
1
6
Order By: Relevance
“…The parenteral route is utilised due to the unpredictability of absorption of oral medications. For exacerbations of colic, the antispasmodic hyoscine butylbromide is of benefit and less sedating than hyoscine hydrobromide (Anthony et al, 2007;Ripamonti et al, 2008 Level IV). Decompression and reduction in secretions may also assist with pain.…”
Section: Malignant Bowel Obstructionmentioning
confidence: 99%
“…The parenteral route is utilised due to the unpredictability of absorption of oral medications. For exacerbations of colic, the antispasmodic hyoscine butylbromide is of benefit and less sedating than hyoscine hydrobromide (Anthony et al, 2007;Ripamonti et al, 2008 Level IV). Decompression and reduction in secretions may also assist with pain.…”
Section: Malignant Bowel Obstructionmentioning
confidence: 99%
“…MBO is a common palliative care problem, encountered in 5-51% of patients with ovarian cancer, 10-28% of patients with colorectal cancer and 3-15% of patients with other types of cancer (1,2,(5)(6)(7)(8). In our study, the type of cancer most commonly responsible for MBO was found to be colorectal adenocarcinoma (55%).…”
Section: Discussionmentioning
confidence: 68%
“…Although it may occur at any stage, it is most commonly associated with end-stage cancer (1). Retrospective reviews demonstrated that 10-50% of patients with advanced cancer stage will develop MBO during the course of their disease and suffer from intractable abdominal pain, nausea and vomiting, which result in a poor quality of life (QOL), mental and emotional problems (2). Multimodality treatments, including surgery, palliative radiotherapy, chemotherapy and total parenteral nutrition formulas, may be used to relieve the symptoms in patients with MBO; however, there is currently no consensus regarding the optimal treatment strategy and no strong evidence supporting the efficacy of any treatment in improving QOL and prolonging survival.…”
Section: Introductionmentioning
confidence: 99%
“…Other drug groups used in patients with neuropathic pain component comprise local anesthetics and antiarrhytmics (Freynhagen & Bennett, 2009). Opioid analgesics should be supplemented with spasmolytics in patients with visceral colicky pain, especially in the course of bowel obstruction (Ripamonti et al, 2008).…”
Section: Omentioning
confidence: 99%